Brief: Oxigene receives fast track status from U.S. FDA for CA4P
30/03/2016 13:30
March 30 (Reuters) - Oxigene Inc OXGN.O :
* Oxigene receives fast track designation from U.S. FDA for
CA4P
Source text for Eikon: urn:newsml:reuters.com:*:nGNXMQGTMa
Further company coverage: OXGN.O
(Bengaluru Newsroom: +1-646-223-8780)
Recent news on Oncotelic Therapeutics
See all newsBrief: Oncotelic Therapeutics Emerging As Leader With New Independent JV Valuation
Brief: Oncotelic Therapeutics - JV Is Preparing For A Potential Initial Public Offering On The Hong Kong Stock Exchange In Late 2026
Brief: Oncotelic Therapeutics To Sell Its Necroptosis Cancer Therapy Assets To Mosaic Immunoengineering
Brief: Oncotelic Announces Initiation Of Clinical Study In Non-Small Lung Cell Cancer
Brief: Oncotelic Initiates Clinical Trials Evaluating Ot-101 Against Pediatric Gliomas